Clinical Trials Logo

Filter by:
NCT ID: NCT00819585 Completed - Gout Clinical Trials

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

Start date: December 2008
Phase: Phase 2
Study type: Interventional

The 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled core study investigated the prophylactic effect of canakinumab on the signs and symptoms of acute flares in chronic gout patients initiating allopurinol therapy. The core study was followed by a 24-week open-label, multicenter extension study to assess the safety, tolerability, and efficacy of canakinumab in patients with gout who were given canakinumab at the time of gout flare.

NCT ID: NCT00819156 Completed - Prostate Cancer Clinical Trials

Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer

Start date: February 2004
Phase: Phase 2
Study type: Interventional

The purpose of the trial was to evaluate the safety and efficacy of degarelix when comparing six different doses. The patients participating in the trial were treated with degarelix every month for a year. During the treatment the patients had to visit the clinic for investigations. Blood samples for testosterone, dihydrotestosterone, luteinizing hormone, follicle stimulating hormone, and Prostate Specific Antigen were taken and analysed throughout the trial.

NCT ID: NCT00819091 Completed - Clinical trials for Diabetes Mellitus, Type 2

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

Start date: December 2008
Phase: Phase 3
Study type: Interventional

Efficacy and safety of BI 1356 compared to placebo in patients with type 2 diabetes who have insufficient glycaemic control despite treatment with a sulfonylurea drug.

NCT ID: NCT00818623 Completed - Prostate Cancer Clinical Trials

Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients

Start date: November 2002
Phase: Phase 2
Study type: Interventional

The purpose of this trial was to find an optimal dose for a new trial drug - degarelix (FE200486) - in the treatment of prostate cancer. Furthermore the safety of the drug was studied. Patients participating were treated with FE200486 on one occasion. Thereafter they came in for visits following a specific schedule until blood samples showed that there was no further effect.

NCT ID: NCT00814619 Completed - Colorectal Cancer Clinical Trials

Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer

Start date: November 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor, and giving radiation therapy in higher doses over a shorter period of time, may kill more tumor cells and have fewer side effects. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving capecitabine together with 3-D conformal radiation therapy is more effective with or without panitumumab in treating patients with advanced rectal cancer. PURPOSE: This randomized phase II trial is studying giving capecitabine together with radiation therapy to see how well it works with or without panitumumab in treating patients with advanced rectal cancer.

NCT ID: NCT00813605 Completed - Clinical trials for Metastatic Colorectal Cancer

QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma

Start date: March 2009
Phase: Phase 2
Study type: Interventional

This is a phase 2, multicenter, randomized, double-blind, double-dummy, placebo-controlled, three-arm trial to be conducted in the United States, Europe, and Asia. Approximately 150 eligible KRAS-mutant metastatic colorectal cancer subjects who have failed first line fluoropyrimidine and oxaliplatin-based regimen with or without anti-VEGF therapy will be randomized in a 1:1:1 ratio to receive AMG 479 placebo plus AMG 655 with FOLFIRI, or AMG 479 plus AMG 655 placebo with FOLFIRI, or AMG 479 placebo plus AMG 655 placebo with FOLFIRI

NCT ID: NCT00812916 Completed - Atrial Fibrillation Clinical Trials

European Carto® XP REgistry for Validating Specialized CFAE SOftware

EXPRESSO
Start date: September 2008
Phase: N/A
Study type: Observational

The purpose of this prospective observational study (registry) is to determine the acute success rate of a complex fractionated atrial electrogram (CFAE) guided ablation procedure using a dedicated software and to determine the functionality and performance of the CFAE software in patients with a type of persistent atrial fibrillation (AF) in routine clinical practice.

NCT ID: NCT00812175 Completed - Clinical trials for Carcinoma, Hepatocellular

Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib

GIDEON
Start date: January 2009
Phase: N/A
Study type: Observational

In this international non-interventional study safety and clinical data concerning the treatment of patients suffering from Hepatocellular Carcinoma (HCC) will be collected.

NCT ID: NCT00811941 Completed - Alcohol Dependence Clinical Trials

Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence

SENSE
Start date: March 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study is long-term safety, tolerability and efficacy of nalmefene in patients with alcohol dependence.

NCT ID: NCT00810069 Completed - Clinical trials for Major Depressive Disorder

Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder

Start date: November 2008
Phase: Phase 4
Study type: Interventional

This study investigates two different approaches to the change in antidepressant treatment when an initial treatment is not effective: early intervention or delayed intervention. Two hypothesis will be tested: 1. that time to confirmed response is shorter in the early intervention strategy vs. delayed intervention strategy 2. that the time to confirmed remission is shorter in the early intervention strategy compared to delayed intervention strategy.